In other words, we think those patients might have two subclones of cancer cells, one is driven by EGFR exon 21 p.L858R and the other is driven by EGFR 19-Del, and both of them are likely to be sensitive to EGFR TKIs. The gene discussed is EGFR; the disease is cancer.